Lenvatinib Plus Chemotherapy for pNET Liver Metastases
NCT07835893
Summary
This prospective, non-randomized, concurrent parallel-controlled study will evaluate treatment response and resistance mechanisms in patients with pancreatic neuroendocrine tumors with liver metastases (pNET-LM) receiving second-line systemic therapy after failure of first-line treatment. Eligible patients will receive either lenvatinib combined with chemotherapy or chemotherapy alone according to the study protocol and clinical treatment strategy. The clinical efficacy and safety of the two treatment strategies will be evaluated using objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events. Peripheral blood samples will be collected before treatment, during early treatment, and at disease progression. Circulating cell-free DNA (cfDNA) and peripheral blood mononuclear cells (PBMCs) will be analyzed to investigate molecular and immune changes associated with treatment response, primary resistance, and acquired resistance. The study aims to identify potential biomarkers for predicting treatment response and to improve understanding of resistance mechanisms in pNET-LM.
Eligibility
Inclusion Criteria: * Inclusion Criteria: * Age 18 to 75 years. * Histologically or cytologically confirmed pancreatic neuroendocrine tumor. * Radiologically confirmed liver metastases. * Disease progression or treatment failure after first-line systemic therapy, with eligibility for second-line treatment. * At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate hematologic, hepatic, and renal function as assessed by the investigator. * Life expectancy of at least 12 weeks. * Ability to understand and willingness to sign a written informed consent form. Exclusion Criteria: * Poorly differentiated neuroendocrine carcinoma or neuroendocrine tumor originating from a site other than the pancreas. * Previous treatment with lenvatinib. * Uncontrolled or clinically significant cardiovascular disease, including uncontrolled hypertension. * Active severe infection or other uncontrolled serious systemic disease. * Known central nervous system metastases that are symptomatic or uncontrolled. * Pregnancy or breastfeeding. * Participation in another interventional clinical study that may interfere with the outcomes of this study. * Any other condition that, in the opinion of the investigator, may make the participant unsuitable for participation in this study.
Conditions3
Interventions1
Related trials
- A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours — LaNova Medicines Limited
- A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma — Akeso
- A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer — Sichuan Baili Pharmaceutical Co., Ltd.
- A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence — Tianjin Medical University Cancer Institute and Hospital
- A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma — Zhejiang University
- An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy. — Peking Union Medical College Hospital
- CARE1 Pragmatic Clinical Trial — Gustave Roussy, Cancer Campus, Grand Paris
- Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma — Hunan Cancer Hospital
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07835893